Viatris Inc.

NasdaqGS:VTRS Lagerbericht

Marktkapitalisierung: US$20.1b

Viatris Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Viatris wird ein jährliches Gewinn- und Umsatzwachstum von 50.9% bzw. 1.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 44.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.9% betragen.

Wichtige Informationen

50.9%

Wachstumsrate der Gewinne

44.84%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum11.9%
Wachstumsrate der Einnahmen1.8%
Zukünftige Eigenkapitalrendite21.87%
Analystenabdeckung

Good

Zuletzt aktualisiert09 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • May 11

Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating

Summary Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now. Read the full article on Seeking Alpha
Narrativ-Update • May 03

VTRS: Cost Progress And FY26 Outlook Will Support Future Upside Potential

Narrative Update: Viatris The updated analyst price target for Viatris moves to $20 from $18. Analysts link the change to cost savings progress, FY26 guidance above prior consensus, and expectations for revenue growth and earnings efficiency.
Narrativ-Update • Apr 19

VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential

Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.
Narrativ-Update • Apr 04

VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential

Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.
Narrativ-Update • Mar 21

VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential

Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.
Narrativ-Update • Mar 07

VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations

Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.
Narrativ-Update • Feb 20

VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk

Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.
Narrativ-Update • Feb 06

VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential

Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.
Narrativ-Update • Jan 23

VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential

Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.
Narrativ-Update • Jan 09

VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns

Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.
Narrativ-Update • Dec 25

VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance

Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.
Narrativ-Update • Dec 11

VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance

Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.
Narrativ-Update • Nov 27

VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead

Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.
Narrativ-Update • Nov 13

VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead

The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.
Narrativ-Update • Oct 30

VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth

Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.
Narrativ-Update • Oct 15

Aging Populations And Asia Markets Will Unlock Future Value

Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.
Narrativ-Update • Aug 27

Aging Populations And Asia Markets Will Unlock Future Value

The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
User avatar
Neues Narrativ • Apr 22

New Product Launches And Expense Savings Will Strengthen Future Operations

New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.
Seeking Alpha • Feb 27

Viatris: One Swallow Doesn't Make A Summer

Summary Viatris Inc. missed estimates on sales and earnings per share. The company's 2025 guidance reveals significant challenges, including a $385 million EBITDA hit from issues at the Indore plant. We would stay out of VTRS stock. Read the full article on Seeking Alpha
Seeking Alpha • Jan 24

Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out

Summary Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of "Phase 1" of its business transformation, and initiation of "Phase 2" of their strategic plan — returning to growth. Viatris markets a mix of generic and established brand drugs, with the latter's revenues declining due to patent expiries and market competition. In a sense, the "buy"/"sell" equation is simple: grow the business in 2025, and the stock price will rise. If the top-line shrinks, investors may lose faith. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes

Summary We have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that has not worked till now and why we are getting ready to trade this. Read the full article on Seeking Alpha
Seeking Alpha • Nov 08

Bargain Priced Viatris Reports Strong Q3 Earnings Results

Summary Investors cheered Viatris' Q3 2024 earnings release Thursday, bidding the stock up +13.5%. Generic pharmaceuticals have performed well and Viatris is a top idea in the space that should flourish with greater than average product launches due to the Inflation Reduction Act. Recent earnings show revenue stabilization, driven by successful new product launches, with fewer divestitures moving forward. With a stronger balance sheet and increased capital for business development, Viatris is well-positioned for share-price appreciation and dividend growth. Viatris remains a strong buy due to new product launches, a bargain valuation at 5x forward earnings, and significant debt reduction to 3x EBITDA by year's end. Read the full article on Seeking Alpha
Seeking Alpha • Oct 22

Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy

Summary Viatris Inc. stock has experienced significant volatility since its 2020 inception, driven by disappointing early performance, asset sales, and fluctuating market expectations. Despite low P/E and P/S ratios suggesting a “screaming buy,” falling revenues and substantial debt challenge Viatris' growth prospects. CEO Scott Smith's “Phase 2” strategy focuses on new product launches and debt reduction, aiming to offset declining sales of older generics and established brands. Viatris' future growth hinges on its innovative pipeline and global infrastructure, with potential blockbuster drugs and a streamlined business model promising profitability and shareholder returns. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:VTRS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202815,2719771,7472,8495
12/31/202715,0394041,7562,8058
12/31/202614,750961,7132,2958
3/31/202614,563-2961,6562,169N/A
12/31/202514,300-3,5151,8512,316N/A
9/30/202514,124-3,6911,5991,983N/A
6/30/202514,116-3,4681,6952,064N/A
3/31/202514,330-3,7901,8392,224N/A
12/31/202414,739-6341,9442,303N/A
9/30/202415,049-8831,8932,389N/A
6/30/202415,239-6461,8842,397N/A
3/31/202415,361-562,0002,543N/A
12/31/202315,427552,3252,900N/A
9/30/202315,4661,8322,0232,474N/A
6/30/202315,6021,8542,0452,508N/A
3/31/202315,8001,9042,3322,785N/A
12/31/202216,2632,0792,5102,999N/A
9/30/202216,7288042,8353,333N/A
6/30/202217,1877613,0353,550N/A
3/31/202217,6481682,7793,307N/A
12/31/202117,886-1,2692,5083,017N/A
9/30/202117,168-1,9211,7842,530N/A
6/30/202115,604-2,0471,2961,969N/A
3/31/202113,757-1,7281,1661,790N/A
12/31/202011,946-6705511,232N/A
9/30/202011,5142661,5391,882N/A
6/30/202011,5042711,5021,845N/A
3/31/202011,624631,6872,135N/A
12/31/201911,50117N/A1,804N/A
9/30/201911,38748N/A1,753N/A
6/30/201911,28834N/A1,919N/A
3/31/201911,245240N/A1,680N/A
12/31/201811,434353N/A2,342N/A
9/30/201811,594546N/A2,201N/A
6/30/201811,719457N/A2,096N/A
3/31/201811,873717N/A2,234N/A
12/31/201711,908696N/A2,065N/A
9/30/201711,937869N/A1,919N/A
6/30/201712,007661N/A2,571N/A
3/31/201711,605533N/A2,420N/A
12/31/201611,077480N/A2,047N/A
9/30/201610,300257N/A2,350N/A
6/30/20169,938806N/A2,124N/A
3/31/20169,749805N/A1,822N/A
12/31/20159,429848N/A2,009N/A
9/30/20159,021842N/A1,483N/A
6/30/20158,410913N/A949N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VTRS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.5%).

Ertrag vs. Markt: VTRS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: VTRS wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: VTRSDie Einnahmen des Unternehmens (1.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).

Hohe Wachstumseinnahmen: VTRSDie Einnahmen des Unternehmens (1.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: VTRSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.9%)

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/15 10:45
Aktienkurs zum Tagesende2026/05/15 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Viatris Inc. wird von 31 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jasper HellwegArgus Research Company
Glen SantangeloBarclays
Aaron GalBernstein